• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Controversial Lancet study linking HCQ, deaths in COVID-19 treatment retracted

By PTI
|

Boston, June 05: The authors of the research linking the malaria drug hydroxychloroquine and increased death risk during COVID-19 treatment have retracted the Lancet study as they were unable to share the full dataset for an independent peer-review.

Controversial Lancet study linking HCQ, deaths in COVID-19 treatment retracted

"Several concerns were raised with respect to the veracity of the data and analyses conducted by Surgisphere Corporation and its founder and our co-author, Sapan Desai, in our publication," the authors of the study wrote in the retraction statement published in The Lancet journal.

Coronavirus: Study reveals young COVID-19 patients are subjected to risk of stroke

    Centre issues guidelines for the reopening of malls, offices and religious places | Oneindia News

    When an independent third-party peer review of Surgisphere was initiated with the consent of the co-authors of the study to evaluate the origination of the database, and to replicate the analyses presented in the paper, the peer reviewers noted that Surgisphere would not transfer the full dataset.

    They were also unable to obtain details on client contracts to their servers for analysis since such transfer would violate client agreements with the company and confidentiality requirements.

    "Based on this development, we can no longer vouch for the veracity of the primary data sources. Due to this unfortunate development, the authors request that the paper be retracted," the retraction statement noted.

    For Daily Alerts
    Get Instant News Updates
    Enable
    x
    Notification Settings X
    Time Settings
    Done
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more